Havrix 1440 And Havrix Junior 1,0 mL & 0,5 mL Suspension for injection
PDF Leaflet Revision Date: 12 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Active immunisation against hepatitis A virus infection.
Dosage (summary)
Adults: 1 mL (HAVRIX 1440); Children: 0.5 mL (HAVRIX JUNIOR). Booster at 6-12 months.
Special Populations
- HIV-infected persons
- Haemodialysis patients
- Chronic liver disease
Pregnancy & Breastfeeding
Use in pregnancy and lactation only when clearly needed.
Key Drug Interactions
- Concomitant use with other inactivated vaccines
- Immunoglobulins
Contraindications
- Hypersensitivity to vaccine components
Common side effects
- Headache
- Irritability
- Pain at injection site
- Fatigue
Counselling Points
- Remain under supervision for 30 mins post-vaccination
- Firm pressure at injection site for bleeding disorders
Serious warnings
- Do not freeze
- Postpone in acute severe febrile illness
- Monitor for anaphylaxis
Important Disclaimer
The Havrix 1440 And Havrix Junior 1,0 mL & 0,5 mL Suspension for injection professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
